Trials / Conditions / Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive

22 registered clinical trials studyying Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Terminated	Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia NCT04526795	M.D. Anderson Cancer Center	Phase 1
Completed	Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies NCT04681105	City of Hope Medical Center	Phase 1
Withdrawn	Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer NCT03739606	City of Hope Medical Center	Phase 2
Active Not Recruiting	Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leuk NCT04188405	M.D. Anderson Cancer Center	Phase 2
Terminated	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524	OHSU Knight Cancer Institute	Phase 1
Withdrawn	Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem C NCT03807063	Fred Hutchinson Cancer Center	Phase 1
Recruiting	Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndr NCT03630991	M.D. Anderson Cancer Center	Phase 1
Terminated	Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Rela NCT03576547	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Terminated	Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelate NCT03246906	Fred Hutchinson Cancer Center	Phase 2
Active Not Recruiting	Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer U NCT02861417	M.D. Anderson Cancer Center	Phase 2
Terminated	Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia NCT02730195	Emory University	Phase 2
Terminated	Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HS NCT02728700	Stanford University	Phase 1
Completed	Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and C NCT02311998	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Completed	Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Rela NCT02220985	Fred Hutchinson Cancer Center	Phase 2
Recruiting	Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk NCT02115295	M.D. Anderson Cancer Center	Phase 2
Completed	Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leuke NCT01904136	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Completed	Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignan NCT01823198	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Completed	Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Tran NCT01822509	National Cancer Institute (NCI)	Phase 1
Recruiting	Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic P NCT01746836	M.D. Anderson Cancer Center	Phase 2
Completed	Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell NCT01527045	Fred Hutchinson Cancer Center	Phase 2
Completed	Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by NCT00789776	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Completed	Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease i NCT00105001	Fred Hutchinson Cancer Center	Phase 2